Eli Lilly and Company (LLY) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
LLY's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
LLY Revenue Analysis (2013–2024)
As of February 28, 2026, Eli Lilly and Company (LLY) generated trailing twelve-month (TTM) revenue of $59.42 billion, reflecting explosive growth of +53.9% year-over-year. The most recent quarter (Q3 2025) recorded $17.60 billion in revenue, up 13.1% sequentially.
Looking at the longer-term picture, LLY's 5-year compound annual growth rate (CAGR) stands at +15.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $45.04 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows LLY's business is primarily driven by Product (90%), and Collaboration and Other Revenue (10%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including JNJ (+3.7% YoY), AZN (+8.6% YoY), and BMY (+1.3% YoY), LLY has outperformed the peer group in terms of revenue growth. Compare LLY vs JNJ →
Peer Comparison
Compare LLY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LLYCurrent | $59.4B | +53.9% | +15.1% | 38.9% | |
| JNJ | $88.8B | +3.7% | +1.6% | 24.9% | |
| AZN | $58.7B | +8.6% | +17.2% | 23.4% | |
| BMY | $48.3B | +1.3% | +13.1% | 20.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $45.04B | +32.0% | $36.62B | 81.3% | $17.50B | 38.9% |
| 2023 | $34.12B | +19.6% | $27.04B | 79.2% | $10.79B | 31.6% |
| 2022 | $28.54B | +0.8% | $21.91B | 76.8% | $8.65B | 30.3% |
| 2021 | $28.32B | +15.4% | $21.01B | 74.2% | $7.93B | 28.0% |
| 2020 | $24.54B | +9.9% | $19.06B | 77.7% | $7.21B | 29.4% |
| 2019 | $22.32B | +3.8% | $17.60B | 78.8% | $6.00B | 26.9% |
| 2018 | $21.49B | +7.6% | $16.81B | 78.2% | $6.03B | 28.0% |
| 2017 | $19.97B | -5.9% | $15.53B | 77.7% | $4.25B | 21.3% |
| 2016 | $21.22B | +6.3% | $15.51B | 73.1% | $3.87B | 18.2% |
| 2015 | $19.96B | +1.7% | $14.92B | 74.8% | $3.59B | 18.0% |
See LLY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LLY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare LLY vs AGIO
See how LLY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is LLY's revenue growth accelerating or slowing?
LLY revenue is accelerating at +53.9% year-over-year, exceeding the 5-year CAGR of +15.1%. TTM revenue reached $59.4B. Growth momentum has increased versus prior periods.
What is LLY's long-term revenue growth rate?
Eli Lilly and Company's 5-year revenue CAGR of +15.1% reflects the sustained expansion pattern. Current YoY growth of +53.9% is above this long-term average.
How is LLY's revenue distributed by segment?
LLY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.